Part 1: Psilocybin in the treatment of substance use disorders

Presenter:
Christopher Pittenger, MD, PhD
Director, Yale Program for Psychedelic Science, Psychiatry; Director, Yale Center for Brain and Mind Health, Yale School of Medicine; Director, Yale OCD Research Clinic, Psychiatry; Director, Neuroscience Research Training Program Yale Department of Psychiatry
New Haven, Connecticut

Part 2: Reviewing the Design, Outcomes, and the Limitations of the Studies/Data Collection of Large Randomized Controlled Trials

Presenter:
Suresh Muthukumaraswamy, PhD 

Associate Professor 

School of Pharmacy

Faculty of Medical and Health Sciences

The University of Auckland 

Waipapa Taumata Rau

Part 3: Ethical Considerations and Concerns About Patient Safety When Treating with Psychedelics 

Presenter:
Paul Appelbaum, MD 

Psychiatry, Forensic Psychiatry 

Elizabeth K. Dollard Professor of Psychiatry, Medicine and Law, and Director, Division of Law, Ethics and Psychiatry at Columbia  

New York, New York

Panel discussion 

Moderator:
Karen Drexler, MD

Medical Director, AAAP

Department of Psychiatry and Behavioral Sciences Associate Professor 

Emory University School of Medicine 

Atlanta, Georgia

Panelist:
Nora Volkow, MD 

Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health

Panelist:
Bertha Madras, PhD 

Professor of Psychobiology 

Harvard Medical School

McLean Hospital

Boston, Massachusetts